New precision medicine treatments can transform once terminal, acute diseases like ovarian cancer into chronic ones.
Historically, more than 75 percent of ovarian cancers would eventually recur, at which point they are not curable. But recent FDA approvals for a new class of oral drugs called parp inhibitors have resulted in significantly improved survival for newly diagnosed ovarian cancer patients.
However, the effectiveness of these treatments is dependent on genetic and tumor mutations. A complex process of multiple genetic and tumor tests, each of which can take weeks to complete, must be completed within four months of diagnosis to ensure optimal treatment. When we started this work, the vast majority of Penn Medicine patients newly diagnosed with ovarian cancer were starting the genetic testing process. But, only about half were completing it in time, with drop-offs happening at numerous points along the way.
Precision Medicine Activated (PreAct) is a model that combines elements of technology and high-touch follow-up to optimize the genetic and tumor testing pathway for providers and patients.
PreAct uses standardized inclusion criteria to identify which patients need genetic testing and subsequent reflex tumor testing. With help from Agent, all patient information is automatically aggregated into a dashboard view to allow for easy status and results tracking by care teams.
When it's time for action, automated alerts are pushed to patients and care team members. And, for patients who drop off, PreAct features a high-touch workflow that can be activated to intervene before it's too late to complete the testing pathway.